B7-H3 is emerging as one of the most promising targets in cancer therapy because it is highly expressed across many solid tumors while remaining limited in normal tissues. Several antibody-drug conjugates (ADCs) targeting B7-H3 are now showing encouraging early results in lung, prostate, and gynecologic cancers.
In small cell lung cancer, Ifinatamab deruxtecan received FDA priority review in April 2026 for previously treated extensive-stage disease. In the phase 2 IDeate-Lung01 study, the drug achieved a 48.2% response rate, with median progression-free survival of 4.9 months and overall survival of 10.3 months. Common toxicities included nausea, anemia, and neutropenia.
In metastatic castration-resistant prostate cancer, vobramitamab duocarmazine and risvutatug rezetecan both demonstrated promising response rates and PSA reductions, though toxicity remained a challenge for some patients.
Meanwhile, SYS6043 showed notable activity in heavily pretreated ovarian, endometrial, and cervical cancers, including response rates above 45% in ovarian cancer with manageable safety findings and no treatment-related deaths.